ASMB - Assembly Biosciences Inc

https://www.assemblybio.com

Momentum: Bearish

Recent News

Assembly Biosciences ( ASMB ) Reports Q1 Loss, Tops Revenue Estimates

Zacks Commentary • 4 months ago • score: 0.07

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 41.79% and 21.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.

52W High

$27.17

52W Low

$7.75

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.69

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.42

EV/Revenue (<3 favorable)

3.33

P/S (TTM) (<3 favorable)

11.15

P/B (<3 favorable)

10.09

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

38.52%

Institutions (25–75% balanced)

25.43%

Shares Outstanding

7,672,300

Float

3,593,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

33,247,000

Gross Profit (TTM)

-25,524,000

EPS (TTM)

-5.56

Profit Margin (>10% good)

-1.17%

Operating Margin (TTM) (higher better)

-1.15%

ROE (TTM) (>15% strong)

-1.48%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.13

Momentum

Bearish momentum

Value

0.1641

0.3103

Trend

Falling

Signal Cross

No cross

As of

Sep. 11, 2025